These results offer new insights into BLCA’s molecular drivers and nominate the ARHGEF12/RhoA/ROCK/PI3K/AKT cascade as a promising therapeutic target to overcome treatment resistance in BLCA. This evidence concerns the gene ARHGEF12 and bladder transitional cell carcinoma.